Christopher P Venner (Christopher Venner)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 7

Top Topics

Peritoneal Dialysis

Multiple Myeloma

Diffuse Large B Cell Lymphoma

Prognostic Factors

Top Venues

Leukemia & lymphoma

American journal of hematology

European journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Jowon Laura Kim, Alina S Gerrie, Kerry Joane Savage, Diego R Villa, David W Scott, Jeffrey W Craig, Pedro Farinha, Brian Skinnider, Graham Slack, Joseph M Connors, Laurie Helen Sehn, Christopher P Venner, Ciara Louise Freeman
Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis. Leukemia & lymphoma 65 (3) (2023)
Jowon Laura Kim, Alina S Gerrie, Kerry Joane Savage, Diego R Villa, David W Scott, Jeffrey W Craig, Pedro Farinha, Brian Skinnider, Graham Slack, Joseph M Connors, Laurie Helen Sehn, Christopher P Venner, Ciara Louise Freeman
Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis. Leukemia & lymphoma (2023)
Jowon Laura Kim, Alina S Gerrie, Kerry Joane Savage, Diego R Villa, David W Scott, Jeffrey W Craig, Pedro Farinha, Brian Skinnider, Graham Slack, Joseph M Connors, Laurie Helen Sehn, Christopher P Venner, Ciara Louise Freeman
Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis. Leukemia & lymphoma 65 (3) (2023)
Richard LeBlanc, Hira S Mian, Donna Reece, Jiandong Su, Esther Masih-Khan, Michael Chu, Victor H Jimenez-Zepeda, Michael Sebag, Kevin Song, Martha Louzada, Rami Kotb, Alissa Visram, Darrell White, Julie Stakiw, Anthony Reiman, Muhammad Aslam, Debra Bergstrom, Rayan Kaedbey, Engin Gul, Christopher P Venner
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis. European journal of haematology (2023)
Vaishali Sanchorawala, Giovanni Palladini, Monique C Minnema, Arnaud Jaccard, Hans C Lee, Simon Gibbs, Peter Mollee, Christopher P Venner, Jin Lu, Stefan Schönland, Moshe E E Gatt, Kenshi Suzuki, Kihyun Kim, María Teresa Cibeira, Meral Beksac, Edward Libby, Jason Valent, Vania Tietsche de Moraes Hungria, Sandy W Wong, Michael Rosenzweig, Naresh Bumma, Dominique Chauveau, Katharine S Gries, John Fastenau, Nam Phuong Tran, Xiang Qin, Sandra Y Vasey, Brendan M Weiss, Jessica Vermeulen, Kai Fai Ho, Giampaolo Merlini, Raymond L Comenzo, Efstathios Kastritis, Ashutosh D Wechalekar
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study. American journal of hematology 97 (6) (2022)
Sosana Delimpasi, Maria Victoria Mateos, Holger W Auner, Maria Gavriatopoulou, Meletios- Athanasios Dimopoulos, Hang Quach, Halyna Pylypenko, Roman Hájek, Xavier Leleu, Tuphan Kanti Dolai, Dinesh Kumar Sinha, Christopher P Venner, Reuben Benjamin, Mamta Krishnan Garg, Vadim Doronin, Yair Levy, Phillipe Moreau, Yi Chai, Melina Arazy, Jatin Shah, Sharon Shacham, Michael G Kauffman, Paul Gerard Richardson, Sebastian Grosicki
Efficacy and Tolerability of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Standard Twice-Weekly Bortezomib and Dexamethasone in Previously Treated Multiple Myeloma with Renal Impairment: Subgroup Analysis from the BOSTON Study. American journal of hematology (2021)
Christopher P Venner, Richard LeBlanc, Irwindeep Sandhu, Darrell White, Andrew R Belch, Donna E Reece, Christine Chen, Sean Dolan, Marc Lalancette, Martha Louzada, Andrea Kew, Arleigh McCurdy, Bethany Monteith, Tony Reiman, Gail McDonald, Max Sherry, Engin Gul, Bingshu E Chen, Annette E Hay
Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN-003/MYX.1 single arm phase II trial. American journal of hematology 96 (5) (2021)